{"log_id": 4664539376046721500, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 2.5e-05, "average": 0.996728, "min": 0.983041}, "location": {"width": 613, "top": 209, "height": 39, "left": 242}, "words": "如同其它抗抑郁药,文拉法辛可能会引起惊厥。有惊厥史的患者应慎用"}, {"probability": {"variance": 2.6e-05, "average": 0.993748, "min": 0.985264}, "location": {"width": 83, "top": 268, "height": 25, "left": 232}, "words": "癫痫发作"}, {"probability": {"variance": 2.7e-05, "average": 0.996547, "min": 0.982091}, "location": {"width": 734, "top": 299, "height": 42, "left": 246}, "words": "在上市前的临床研究中,所有的705例接受本品缓释胶囊治疗的抑郁症患者和1381例"}, {"probability": {"variance": 0, "average": 0.944523, "min": 0.944523}, "location": {"width": 23, "top": 331, "height": 24, "left": 1126}, "words": "督"}, {"probability": {"variance": 0.001453, "average": 0.988202, "min": 0.761494}, "location": {"width": 778, "top": 346, "height": 41, "left": 201}, "words": "GAD患者中没有出现癫病发作。在所有文拉法辛常释制剂上市前研究中,接受不同剂量治"}, {"probability": {"variance": 0.003025, "average": 0.984099, "min": 0.662542}, "location": {"width": 780, "top": 392, "height": 41, "left": 201}, "words": "疗的患者中有0.3%(8/3082)出现癫病发作。和其它抗抑郁药物一样,本品应慎用于有癫痫"}, {"probability": {"variance": 0.000312, "average": 0.975496, "min": 0.957824}, "location": {"width": 24, "top": 363, "height": 61, "left": 1131}, "words": "明逢"}, {"probability": {"variance": 0.00049, "average": 0.990098, "min": 0.929442}, "location": {"width": 377, "top": 444, "height": 32, "left": 203}, "words": "发作病史的患者,当患者痫发作时应停药"}, {"probability": {"variance": 0.000953, "average": 0.978338, "min": 0.911361}, "location": {"width": 111, "top": 494, "height": 26, "left": 209}, "words": "0.异常出血"}, {"probability": {"variance": 0.001308, "average": 0.979726, "min": 0.87449}, "location": {"width": 738, "top": 525, "height": 41, "left": 246}, "words": " SSRIS和 SNRIS,包括本品,可能增加出血事件发生的风险。与阿司匹林、非甾体类的"}, {"probability": {"variance": 0.003424, "average": 0.985882, "min": 0.633111}, "location": {"width": 782, "top": 569, "height": 43, "left": 205}, "words": "抗炎药、华法令和其它抗凝药合并使用可能会增加该风险。病例报告和流行病学研究(病例"}, {"probability": {"variance": 0.006678, "average": 0.969703, "min": 0.499567}, "location": {"width": 770, "top": 616, "height": 40, "left": 207}, "words": "对照和组群设计)已经证明干扰5-羟色胺再摄取的药物与胃肠道出血的相关性。与使用SSRI"}, {"probability": {"variance": 0.000113, "average": 0.994649, "min": 0.949254}, "location": {"width": 679, "top": 662, "height": 38, "left": 210}, "words": "和 SNRIS药物相关的出血事件包括瘀斑、血肿、鼻、瘀点和有生命危险的出血"}, {"probability": {"variance": 0.000236, "average": 0.993844, "min": 0.931554}, "location": {"width": 738, "top": 705, "height": 39, "left": 248}, "words": "当本品与非甾体性抗炎药、阿司匹林或其他任何影响凝血的药合用时,患者应注意异常"}, {"probability": {"variance": 9e-06, "average": 0.997962, "min": 0.992745}, "location": {"width": 80, "top": 765, "height": 22, "left": 210}, "words": "出血风险"}, {"probability": {"variance": 0.000187, "average": 0.99413, "min": 0.915187}, "location": {"width": 737, "top": 793, "height": 40, "left": 250}, "words": "抑制5-羟色胺再摄取的药物可导致血小板聚集的异常。服用文拉法辛的患者皮肤及粘膜"}, {"probability": {"variance": 0.002487, "average": 0.983721, "min": 0.760956}, "location": {"width": 775, "top": 838, "height": 41, "left": 211}, "words": "出血,包括胃肠道出血的风险可能增加。因此,和其它5-羟色胺再摄取抑制剂一样,有出血"}, {"probability": {"variance": 1.5e-05, "average": 0.997479, "min": 0.981645}, "location": {"width": 590, "top": 886, "height": 37, "left": 212}, "words": "倾向的患者,包括使用抗凝药及血小板抑制剂的患者应慎用文拉法辛"}, {"probability": {"variance": 0.001707, "average": 0.975805, "min": 0.868333}, "location": {"width": 192, "top": 940, "height": 25, "left": 214}, "words": "11.血清胆固醇的升高"}, {"probability": {"variance": 0.006365, "average": 0.978844, "min": 0.590687}, "location": {"width": 736, "top": 973, "height": 38, "left": 255}, "words": "在为期3个月以上的安慰剂对照研究中,接受文拉法辛治疗的患者中有5.3%出现有临床"}, {"probability": {"variance": 0.000166, "average": 0.995016, "min": 0.926379}, "location": {"width": 756, "top": 1017, "height": 40, "left": 215}, "words": "意义的血清胆固醇的升高,安慰剂组为0%。在长期治疗的患者中应监测血清胆固醇水平"}, {"probability": {"variance": 0.016045, "average": 0.950061, "min": 0.490371}, "location": {"width": 280, "top": 1068, "height": 32, "left": 217}, "words": "11.间质性肺病和嗜酸细胞性肺炎"}, {"probability": {"variance": 8.4e-05, "average": 0.996668, "min": 0.949214}, "location": {"width": 727, "top": 1104, "height": 39, "left": 265}, "words": "与使用文拉法辛治疗相关的间质性肺病和嗜酸细胞性肺炎鲜有报道。在有进行性呼吸"}, {"probability": {"variance": 0.001397, "average": 0.989246, "min": 0.76543}, "location": {"width": 777, "top": 1148, "height": 40, "left": 215}, "words": "困难、咳嗽或胸部不适症状的文拉法辛使用患者应该考虑这些不良事件的可能性,应该对这"}, {"probability": {"variance": 1.8e-05, "average": 0.998308, "min": 0.977864}, "location": {"width": 512, "top": 1197, "height": 37, "left": 217}, "words": "些患者立刻进行医学评估,并且考虑停止使用文拉法辛治疗"}, {"probability": {"variance": 0.001049, "average": 0.988894, "min": 0.881535}, "location": {"width": 231, "top": 1247, "height": 32, "left": 221}, "words": "2.用于有伴发疾病的患者"}, {"probability": {"variance": 8e-06, "average": 0.997835, "min": 0.990693}, "location": {"width": 736, "top": 1283, "height": 38, "left": 258}, "words": "在上市前,文拉法辛用于伴发躯体疾病患者的经验有限。本品用于伴有躯体疾病的患者"}, {"probability": {"variance": 2e-06, "average": 0.999229, "min": 0.993018}, "location": {"width": 433, "top": 1333, "height": 34, "left": 221}, "words": "可能会影响血液动力学和代谢,处方时需加以注意"}, {"probability": {"variance": 0.000257, "average": 0.994517, "min": 0.902922}, "location": {"width": 725, "top": 1371, "height": 39, "left": 259}, "words": "据报道某些使用文拉法辛的患者可发生剂量相关性的血压升高。在上市后临床经验中"}, {"probability": {"variance": 0.004141, "average": 0.986786, "min": 0.591379}, "location": {"width": 765, "top": 1416, "height": 40, "left": 222}, "words": "有报道需要立即治疗的血压升高的病例。因此使用本品的患者建议监测血压。本品治疗前"}, {"probability": {"variance": 6.7e-05, "average": 0.997118, "min": 0.95027}, "location": {"width": 766, "top": 1460, "height": 43, "left": 221}, "words": "应该对先前存在的高血压进行控制。那些原有基础疾病会因血压升高而恶化的患者应谨慎"}, {"probability": {"variance": 0.001631, "average": 0.991069, "min": 0.747552}, "location": {"width": 737, "top": 1506, "height": 38, "left": 262}, "words": "对于近期心肌梗死或不稳定心脏疾病史的患者,尚缺乏应用文拉法辛的经验,故难以进"}], "language": 3}